Eton Pharmaceuticals (NASDAQ:ETON) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Eton Pharmaceuticals (NASDAQ:ETON) in a research note issued to investors on Wednesday morning,Benzinga reports. HC Wainwright currently has a $33.00 target price on the stock. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q2 2025 earnings at $0.08 EPS, Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.18 EPS, FY2025 earnings at $0.42 EPS, FY2026 earnings at $1.57 EPS, FY2027 earnings at $1.85 EPS, FY2028 earnings at $2.87 EPS and FY2029 earnings at $3.74 EPS.

Several other research firms also recently weighed in on ETON. Craig Hallum lifted their target price on Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. B. Riley assumed coverage on shares of Eton Pharmaceuticals in a research note on Friday, January 10th. They issued a “buy” rating and a $21.00 price target on the stock.

Eton Pharmaceuticals Price Performance

Eton Pharmaceuticals stock opened at $14.22 on Wednesday. Eton Pharmaceuticals has a 1-year low of $3.03 and a 1-year high of $18.41. The company’s 50-day moving average is $15.58 and its 200 day moving average is $11.54. The firm has a market capitalization of $370.45 million, a P/E ratio of -64.64 and a beta of 1.37.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.02) earnings per share for the quarter, hitting the consensus estimate of ($0.02). Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. The firm had revenue of $11.65 million for the quarter, compared to the consensus estimate of $10.53 million. Research analysts anticipate that Eton Pharmaceuticals will post -0.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ETON. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Eton Pharmaceuticals by 86.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after buying an additional 30,167 shares during the period. Wasatch Advisors LP bought a new stake in shares of Eton Pharmaceuticals in the third quarter valued at about $1,431,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Eton Pharmaceuticals in the third quarter worth about $54,000. Parkman Healthcare Partners LLC lifted its stake in Eton Pharmaceuticals by 2.8% in the third quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company’s stock worth $1,561,000 after acquiring an additional 7,029 shares during the period. Finally, Jane Street Group LLC bought a new position in Eton Pharmaceuticals during the 3rd quarter worth about $90,000. 27.86% of the stock is currently owned by hedge funds and other institutional investors.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.